Treatment of Richter's transformation with novel therapies

A Bajwa, A Habib, AS Kittai - Current Hematologic Malignancy Reports, 2024 - Springer
Abstract Purpose of Review This review presents recently published clinical trial data and
ongoing investigations regarding the treatment of Richter's transformation (RT). Recent …

Richter's transformation: Transforming the clinical landscape

A Barrett, N Appleby, H Dreau, CP Fox, T Munir… - Blood Reviews, 2023 - Elsevier
Richter transformation (RT) represents an aggressive histological transformation from
chronic lymphocytic leukaemia, most often to a large B cell lymphoma. It is characterised by …

Practical management of Richter transformation in 2023 and beyond

CE Ryan, MS Davids - … Society of Clinical Oncology Educational Book, 2023 - ascopubs.org
While the past decade has witnessed unprecedented progress for patients with chronic
lymphocytic leukemia (CLL), outcomes for patients with Richter transformation (RT) remain …

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

BT Hill, S Ma, CS Zent, AM Baran, DS Wallace… - Blood …, 2024 - ashpublications.org
Many patients with chronic lymphocytic leukemia (CLL) will develop treatment resistance to
Bruton tyrosine kinase (BTK) inhibitors. Phosphatidylinositol-3-kinase (PI3K) inhibitors …

Update on management of diffuse large B-cell lymphoma Richter's transformation

O Sośnia, B Puła - Acta Haematologica Polonica, 2024 - journals.viamedica.pl
Richter's transformation (RT) is defined as the development of an aggressive lymphoma in 2–
10% of patients with chronic lymphocytic leukemia (CLL). Despite significant advances in …

Are we closer to a standard of care for Richter's syndrome? Novel treatments on the horizon

N Pham, CC Coombs, S O'Brien - Expert Review of Hematology, 2024 - Taylor & Francis
Introduction The therapeutic landscape for chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL) has significantly evolved over the past decade with dramatically …

[HTML][HTML] Chronic lymphocytic leukemia: moving towards new horizons

E IO, ESH CLL - memoinoncology.com
The first-in-class, covalent BTK inhibitor ibrutinib has transformed the treatment of patients
with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). However …